Operative and Conservative Treatment of Uterine Sarcomas

Por Harter, P., El-Khalfaoui, K., Heitz, F., du Bois, A.
Publicado em 2014

Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Por Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., Sehouli, J.
Publicado no Geburtshilfe Frauenheilkd (2015)

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

Por du Bois, A, Vergote, I, Wimberger, P, Ray-Coquard, I, Harter, P, Curtis, L B, Mitrica, I
Publicado em 2012

Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer

Por Harter, P., Schrof, I., Karl, L. M., Hils, R., Kullmann, V., Traut, A., Scheller, H., du Bois, A.
Publicado em 2013

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

Por Harter, P., Mahner, S., Hilpert, F., Runnebaum, I., Ortmann, O., Mustea, A., Sehouli, J., du Bois, A., Wagner, U.
Publicado em 2013

P08.76 Anti-EGFL7 treatment as an add-on for glioma therapy

Por Dudvarski Stanković, N., Jones, D., Harter, P. N., von Deimling, A., Mittelbronn, M., Pfister, S., Schmidt, M. H. H.
Publicado no Neuro Oncol (2016)

O10.03 PHYSIOLOGICAL AND BIOLOGICAL RESPONSES OF HUMAN GLIOBLASTOMAS TO BEVACIZUMAB TREATMENT ASSESSED BY METABOLOMIC FLUX ANALYSIS

Por Fack, F., Espedal, H., Keunen, O., Golebiewska, A., Obad, N., Zheng, L., Gotlieb, E., Harter, P., Niclou, S., Bjerkvig, R.
Publicado em 2014

OS1.4 Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy

Por Foltyn, M., Thiepold, A., Harter, P. N., Baumgarten, P., Mittelbronn, M., Urban, H., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2016)

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Canc...

Por Harter, P., du Bois, A., Mahner, S., Pfisterer, J., Ortmann, O., Marth, C., Fink, D., Hilpert, F., Wagner, U., Sehouli, J.
Publicado no Geburtshilfe Frauenheilkd (2016)

P01.03 mTORC1 activation sensitizes human malignant glioma cells to hypoxia-induced cell death by increasing O2-consumption

Por Thiepold, A. L., Foltyn, M., Urban, H., Heller, S., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2016)

Expression of apolipoprotein E during nerve degeneration and regeneration.

Por Ignatius, M J, Gebicke-Härter, P J, Skene, J H, Schilling, J W, Weisgraber, K H, Mahley, R W, Shooter, E M
Publicado em 1986

Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences

Por Balermpas, P, Rödel, F, Liberz, R, Oppermann, J, Wagenblast, J, Ghanaati, S, Harter, P N, Mittelbronn, M, Weiss, C, Rödel, C, Fokas, E
Publicado em 2014

P01.31 Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death

Por Thiepold, A., Foltyn, M., Urban, H., Voss, M., Hofmann, U., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2017)

Surgical Methods for the Treatment of Uterine Fibroids – Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG

Por Beckmann, M. W., Juhasz-Böss, I., Denschlag, D., Gaß, P., Dimpfl, T., Harter, P., Mallmann, P., Renner, S. P., Rimbach, S., Runnebaum, I., Untch, M., Brucker, S. Y., Wallwiener, D.
Publicado no Geburtshilfe Frauenheilkd (2015)

Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer

Por Kümmel, A., Kümmel, S., Barinoff, J., Heitz, F., Holtschmidt, J., Weikel, W., Lorenz-Salehi, F., du Bois, A., Harter, P., Traut, A., Blohmer, J. U., Ataseven, B.
Publicado no Geburtshilfe Frauenheilkd (2015)

P03.21 Casp9 germline mutation in a family with multiple brain tumors

Por Ronellenfitsch, M. W., Oh, J., Satomi, K., Sumi, K., Harter, P. N., Steinbach, J. P., Felsberg, J., Capper, D., Voegele, C., Schittenhelm, J., Mittelbronn, M., Ohgaki, H.
Publicado no Neuro Oncol (2017)

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

Por Bookman, M A, Okamoto, A, Stuart, G, Yanaihara, N, Aoki, D, Bacon, M, Fujiwara, K, González-Martín, A, Harter, P, Kim, J W, Ledermann, J, Pujade-Lauraine, E, Quinn, M, Ochiai, K
Publicado no Ann Oncol (2017)

Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

Por Denschlag, D., Thiel, F. C., Ackermann, S., Harter, P., Juhasz-Boess, I., Mallmann, P., Strauss, H.-G., Ulrich, U., Horn, L.-C., Schmidt, D., Vordermark, D., Vogl, T., Reichardt, P., Gaß, P., Gebhardt, M., Beckmann, M. W.
Publicado no Geburtshilfe Frauenheilkd (2015)

Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015)

Por Denschlag, D., Thiel, F. C., Ackermann, S., Harter, P., Juhasz-Boess, I., Mallmann, P., Strauss, H.-G., Ulrich, U., Horn, L.-C., Schmidt, D., Vordermark, D., Vogl, T., Reichardt, P., Gaß, P., Gebhardt, M., Beckmann, M. W.
Publicado no Geburtshilfe Frauenheilkd (2015)

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

Por Zang, R Y, Harter, P, Chi, D S, Sehouli, J, Jiang, R, Tropé, C G, Ayhan, A, Cormio, G, Xing, Y, Wollschlaeger, K M, Braicu, E I, Rabbitt, C A, Oksefjell, H, Tian, W J, Fotopoulou, C, Pfisterer, J, du Bois, A, Berek, J S
Publicado em 2011